Data on the occurrence of cervical precancer and cancer among women living with HIV (WLHIV) in Latin American countries (LAC) are scarce and highly heterogeneous.
Methods
We conducted a systematic review summarizing data about the incidence/prevalence of invasive cervical cancer (CC) and high-grade precancerous lesions among WLHIV in LAC. Literature in PubMed and LILACS was searched. The primary outcome was invasive cancer incidence, and prevalence of high-grade lesions as key indicators for the WHO CC elimination strategy. Individual reports on invasive cancer incidence and prevalence of precancerous lesions were obtained, and a random effects meta-analysis was conducted for the latter.
Results
In total, 34,343 WLHIV from four studies reporting CC incidence in seven LAC were included, and 6079 WLHIV from 17 studies reporting prevalence of precancerous lesions in three LAC were included. CC incidence ranged between 136.0 and 398.4 per 100,000 WLHIV (with or without antiretroviral therapy). The weighted prevalence of high-grade lesions was 4.1% (95%CI: 3.8%–6.0%) with a double peak at ages 20–24 and 35–39 years. Differences in prevalence of high-grade lesions were also observed by screening approach: co-testing (11.9%), colposcopy (6.0%), cytology (4.2%), and HPV tests (3.2%).
Conclusions
The high incidence of invasive cancer and prevalence of high-grade lesions underline challenges to reach the WHO’s elimination goal of CC incidence below four per 100,000 among WLHIV. Moreover, the high prevalence of high-grade lesions at younger ages than in the general population is a call to accelerate the implementation of the new WHO screening recommendations in WLHIV.
International Agency for Research on Cancer. Global cancer observatory. Cancer Today. https://gco.iarc.fr/today/home (2022, accessed 01 Apr 2024).
2.
AbrahamAGD’SouzaGJingY, et al.Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr2013; 62(4): 405–413.
3.
MaimanMFruchterRGClarkM, et al.Cervical cancer as an AIDS-defining illness. Obstet Gynecol1997; 89(1): 76–80.
4.
LookerKJRönnMMBrockPM, et al.Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status. J Int AIDS Soc2018; 21(6): e25110.
StelzleDTanakaLFLeeKK, et al.Estimates of the global burden of cervical cancer associated with HIV. Lancet Global Health2021; 9(2): e161–e169.
7.
Ibrahim KhalilAMpungaTWeiF, et al.Age-specific burden of cervical cancer associated with HIV: a global analysis with a focus on sub-Saharan Africa. Int J Cancer2022; 150(5): 761–772.
8.
WanZZhaoJXuL, et al.Global and regional estimates of cervical cancer burden associated with human immunodeficiency virus infection from 1990 to 2019. J Med Virol2023; 95(6): e28891.
DenslowSARositchAFFirnhaberC, et al.Incidence and progression of cervical lesions in women with HIV: a systematic global review. Int J STD AIDS2014; 25(3): 163–177.
11.
LiuGSharmaMTanN, et al.HIV-positive women have higher risk of HPV infection, precancerous lesions, and cervical cancer: a systematic review and meta-analysis. AIDS Lond Engl2018; 32(6): 795–808.
12.
RohnerEBütikoferLSchmidlinK, et al.Cervical cancer risk in women living with HIV across four continents: a multicohort study. Int J Cancer2020; 146(3): 601–609.
13.
Caicedo-MartínezMFernández-DeazaGOrdóñez-ReyesC, et al.High-risk human papillomavirus infection among women living with HIV in Latin America and the Caribbean: a systematic review and meta-analysis. Int J STD AIDS2021; 32(14): 1278–1289.
Caicedo-MartínezMOrdóñez-ReyesCFernández-DeazaG, et al.Cervical cancer epidemiology, prevention and screening among women living with HIV in the americas region: a systematic review protocol. Univ Med2020; 61(4): 80–87.
DownesMJBrennanMLWilliamsHC, et al.Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open2016; 6(12): e011458.
18.
MoherDLiberatiATetzlaffJ, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med2009; 6(7): e1000097.
JalilEMLuzPMQuintanaM, et al.Hybrid capture as a tool for cervical lesions screening in HIV-infected women: insights from a Brazilian cohort. Braz J Infect Dis2018; 22(1): 16–23.
21.
KreitchmannRBajottoHda SilvaDAR, et al.Squamous intraepithelial lesions in HIV-infected women: prevalence, incidence, progression and regression. Arch Gynecol Obstet2013; 288(5): 1107–1113.
22.
MayorAMSantiago-RodriguezEJRios-OlivaresE, et al.Malignancies trends in a hispanic cohort of HIV persons in Puerto Rico before and after cART. Int J Cancer Res2016; 12(2): 92–100.
23.
CambouMCLeviJELakeJE, et al.Time trend analysis of cervical high-risk human papillomavirus (HPV) in HIV-infected women in an urban cohort from Rio de Janeiro, Brazil: the rise of non-16/18 HPV. Int J Infect Dis2015; 41: 17–20.
24.
UribePDUPulidoDLopesG, et al.Cancer incidence in patients diagnosed with acquired immunodeficiency syndrome (AIDS) in Colombia. J AIDS Clin Res2017; 08(05): 692. DOI: 10.4172/2155-6113.1000692.
25.
TanakaLFLatorreMDRGutierrezEB, et al.Trends in the incidence of AIDS-defining and non-AIDS-defining cancers in people living with AIDS: a population-based study from São Paulo, Brazil. Int J STD AIDS2017; 28(12): 1190–1198.
26.
AugeAPFPiatoSFradeAB, et al.Freqüência de Neoplasia Intra-epitelial Cervical em Portadoras do Vírus da Imunodeficiência Humana. Rev Bras Ginecol Obstet2000; 22: 573–577.
27.
VolkowPRubíSLizanoM, et al.High prevalence of oncogenic human papillomavirus in the genital tract of women with human immunodeficiency virus. Gynecol Oncol2001; 82(1): 27–31. DOI: 10.1006/gyno.2001.6244.
28.
LeviJEFinkMCSCantoCLM, et al.Human papillomavirus prevalence, viral load and cervical intraepithelial neoplasia in HIV-infected women. Braz J Infect Dis2002; 6(3): 129–135.
29.
GonçalvesMAGBurattiniMNDonadiEA, et al.Risk factors associated with genital warts in HIV-positive Brazilian women. Tumori2003; 89(1): 9–15. DOI: 10.1177/030089160308900103.
30.
MeloVHDAraújoACLRioSMP, et al.Problemas ginecológicos mais freqüentes em mulheres soropositivas para o HIV. Rev Bras Ginecol Obstet2003; 25(9): 661–666.
31.
CerqueiraDMde S MoraesDCamaraG, et al.High HPV genetic diversity in women infected with HIV-1 in Brazil. Arch Virol2007; 152(1): 75–83.
32.
RosenthalRMSilveiraMFBrumVMA. Associação entre indice de células cd4 e alterações ginecológicas em mulheres hiv-positivo. Braz J Sex Transm Dis2008; 20(2): 104–107.
33.
TeixeiraNCPAraújoACLCorreaCM, et al.Prevalence and risk factors for cervical intraepithelial neoplasia among HIV-infected women. Braz J Infect Dis2012; 16(2): 164–169.
34.
SilvaLMirandaABatalhaR, et al.High-risk human papillomavirus and cervical lesions among women living with HIV/AIDS in Brazilian Amazon, Brazil. Braz J Infect Dis2015; 19(6): 557–562.
35.
CamargoMDel Río-OspinaLSoto-De LeónSC, et al.Association of HIV status with infection by multiple HPV types. Trop Med Int Health2018; 23(11): 1259–1268. DOI: 10.1111/tmi.13142.
36.
Tosato BoldriniNABondi VolpiniLPFreitasLB, et al.Sexually transmitted infections among women living with HIV in a Brazilian city. Braz J Infect Dis2021; 25(1): 101044.
37.
de AndradeACVLuzPMVelasqueL, et al.Factors associated with colposcopy-histopathology confirmed cervical intraepithelial neoplasia among HIV-infected women from Rio De Janeiro, Brazil. PLoS One2011; 6(3): e18297.
38.
MartinsAESLucena-SilvaNGarciaRG, et al.Prevalence of human papillomavirus infection, distribution of viral types and risk factors in cervical samples from human immunodeficiency virus-positive women attending three human immunodeficiency virus-acquired immune deficiency syndrome reference centres in northeastern Brazil. Mem Inst Oswaldo Cruz2014; 109(6): 738–747.
39.
CastilhoJLLeviJELuzPM, et al.A cross-sectional study of high-risk human papillomavirus clustering and cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil. BMC Cancer2015; 15: 478.
CliffordGMTullySFranceschiS. Carcinogenicity of human papillomavirus (HPV) types in HIV-positive women: a meta-analysis from HPV infection to cervical cancer. Clin Infect Dis2017; 64(9): 1228–1235.
44.
WeldegebrealFWorkuT. Precancerous cervical lesion among HIV-positive women in sub-saharan Africa: a systematic review and meta-analysis. Cancer Control2019; 26: 1073274819845872.
45.
WhithamHKHawesSEChuH, et al.A comparison of the natural history of HPV infection and cervical abnormalities among HIV-positive and HIV-negative women in Senegal, Africa. Cancer Epidemiol Biomarkers Prev2017; 26(6): 886–894.
46.
MuwongeRNgo MbusLNgomaT, et al.Socio-demographic and reproductive determinants of cervical neoplasia in seven sub-Sahara African countries. Cancer Causes Control2016; 27(12): 1437–1446.
47.
AbuliziGMijitiPNaizhaerG, et al.At what age should the Uyghur minority initiate cervical cancer screening if screened using careHPV. Cancer Med2021; 10(24): 9022–9029.
48.
GonzálezMMurilloROsorioE, et al.Prevalencia de anormalidades citológicas e histológicas de cuello uterino en un grupo de mujeres en Bogotá, Colombia. Rev Colomb Cancerol2010; 14(1): 22–28.
49.
World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. WHO-Guidelines; 2021. https://www.who.int/publications/i/item/9789240030824 (accessed 14 June 2024).
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
